Article Detail - JE Part A
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R17 - Effective March 12, 2026
Date Posted: March 12, 2026
This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).
Effective Date: March 12, 2026
Summary of Changes:
Under Article Text revised Table 1 row 9 to read "NeXT Personal: WGS Assay Design + Plasma Initial Test (Personalis, Inc)". This revision is effective 3/12/2026.
Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to read "(NSCLC) (Signatera, NeXT Personal)". This revision is due to a new covered test that has successfully completed a TA and is effective for 1/9/2026.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.